Ono Pharmaceutical Co Stock Performance
| OPHLY Stock | USD 3.77 0.08 2.17% |
Ono Pharmaceutical has a performance score of 8 on a scale of 0 to 100. The company holds a Beta of -0.0541, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Ono Pharmaceutical are expected to decrease at a much lower rate. During the bear market, Ono Pharmaceutical is likely to outperform the market. Ono Pharmaceutical right now holds a risk of 1.63%. Please check Ono Pharmaceutical potential upside, as well as the relationship between the accumulation distribution and price action indicator , to decide if Ono Pharmaceutical will be following its historical price patterns.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Ono Pharmaceutical Co are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile essential indicators, Ono Pharmaceutical may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
| Begin Period Cash Flow | 61 B | |
| Total Cashflows From Investing Activities | 6 B |
Ono |
Ono Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 340.00 in Ono Pharmaceutical Co on December 23, 2024 and sell it today you would earn a total of 37.00 from holding Ono Pharmaceutical Co or generate 10.88% return on investment over 90 days. Ono Pharmaceutical Co is currently producing 0.1825% returns and takes up 1.6344% volatility of returns over 90 trading days. Put another way, 14% of traded pink sheets are less volatile than Ono, and 97% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Ono Pharmaceutical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ono Pharmaceutical's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Ono Pharmaceutical Co, and traders can use it to determine the average amount a Ono Pharmaceutical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1117
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | OPHLY | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.63 actual daily | 14 86% of assets are more volatile |
Expected Return
| 0.18 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Ono Pharmaceutical is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ono Pharmaceutical by adding it to a well-diversified portfolio.
Ono Pharmaceutical Fundamentals Growth
Ono Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Ono Pharmaceutical, and Ono Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ono Pink Sheet performance.
| Return On Equity | 0.16 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.26 % | |||
| Operating Margin | 0.35 % | |||
| Current Valuation | 11.13 B | |||
| Shares Outstanding | 1.47 B | |||
| Price To Earning | 18.66 X | |||
| Price To Book | 2.34 X | |||
| Price To Sales | 0.03 X | |||
| Revenue | 361.36 B | |||
| EBITDA | 123.45 B | |||
| Cash And Equivalents | 136.18 B | |||
| Cash Per Share | 92.88 X | |||
| Total Debt | 8.65 B | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 491.93 X | |||
| Cash Flow From Operations | 61.83 B | |||
| Earnings Per Share | 0.58 X | |||
| Total Asset | 739.2 B | |||
| Retained Earnings | 466.64 B | |||
| Current Asset | 218.78 B | |||
| Current Liabilities | 55.22 B | |||
About Ono Pharmaceutical Performance
Evaluating Ono Pharmaceutical's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Ono Pharmaceutical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ono Pharmaceutical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company was founded in 1717 and is headquartered in Osaka, Japan. Ono Pharmaceutical operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 3687 people.Things to note about Ono Pharmaceutical performance evaluation
Checking the ongoing alerts about Ono Pharmaceutical for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Ono Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Evaluating Ono Pharmaceutical's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Ono Pharmaceutical's pink sheet performance include:- Analyzing Ono Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ono Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining Ono Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ono Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ono Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ono Pharmaceutical's pink sheet. These opinions can provide insight into Ono Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Ono Pink Sheet Analysis
When running Ono Pharmaceutical's price analysis, check to measure Ono Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ono Pharmaceutical is operating at the current time. Most of Ono Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Ono Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ono Pharmaceutical's price. Additionally, you may evaluate how the addition of Ono Pharmaceutical to your portfolios can decrease your overall portfolio volatility.